Biohaven Pharmaceutical Hld

Biohaven Ltd. operates as a biopharmaceutical company that focuses on neurological and neuropsychiatric diseases. Its portfolio includes treatments for medical needs including focal epilepsy, obsessive compulsive disorder, spinocerebellar ataxia and spinal muscular atrophy. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously announced Pfizer Inc. acquisition of Biohaven Pharmaceutical Holding Company Ltd.; preliminary proxy statement has been filed with the SEC NURTEC® ODT (rimegepant) TRx volumes grew 11% and net product revenue was $194 million, up sequentially 57% Anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share; non-GAAP adjusted net loss1 for the second quarter was $3.82 per share Featured 31 new and encore presentations, including three late-breakers and three oral presentations, spotlighting robust Nurtec ODT and zavegepant migraine data at the 64th annual scientific meeting of the American Headache Society; oral presentations included first of its kind study in migraine reporting on the safety and benefits of Nurtec ODT when used as preventive treatment and as-needed for acute treatment of migraine Zavegepant nasal spray New Drug Application ("NDA") filing accepted by the U.S. Food and Drug Administration ("FDA"), with a Prescription Drug User Fee Act goal date set for first quarter of 2023 Commenced enrollment in Phase 3 clinical trial assessing efficacy and safety of taldefgrobep alfa in patients with Spinal Muscular Atrophy NEW HAVEN, Conn.

Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments

84% of people with migraine (PwM) and 92% of healthcare professionals (HCPs) agree that worsening migraine leads to poorer mental health Nearly all HCPs (93%) feel mental health impacts a PwM's ability to successfully manage their migraine 77% of PwM worry about stigma of migraine and mental health and are hesitant to discuss with their HCP MOUNT ROYAL, NJ , July 28, 2022 /PRNewswire/ -- The American Migraine Foundation (AMF) and Biohaven Pharmaceuticals (NYSE: BHVN) today announced findings from a new survey about migraine and its impact on mental health. The results of the Migraine and Mental Health Connection Survey reveal that the majority of healthcare professionals (HCPs) and people with migraine (PwM) strongly believe that migraine and mental health significantly impact each other.

American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other

Duke Realty

Hemisphere Media Group

Prologis

NEW YORK , July 26, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hemisphere Media Group, Inc. (NASDAQ: HMTV) 's  sale to a subsidiary of Gato Investments LP for $7.00 per share in cash. If you are a Hemisphere Media shareholder, click here to learn more about your rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HMTV, BHVN, DRE, PLD

Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.

Biohaven (BHVN) Begins Phase III Study on SMA Candidate

NEW HAVEN, Conn. , July 7, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)

LARKSPUR, Calif.--(BUSINESS WIRE)-- #GBMAGILE--Global Coalition for Adaptive Research (LARKSPUR, CA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), and Vigeo Therapeutics -- The Global Coalition for Adaptive Research (GCAR) in collaboration with Biohaven and Vigeo Therapeutics, today announced the activation of Biohaven's troriluzole and Vigeo's VT1021 in GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment). GBM AGILE is a revolutionary patient-centered, adaptive platform t

Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven's Troriluzole and Vigeo'S VT1021 in GBM AGILE Trial

-  Nurtec ODT open-label extension study is the first of its kind evaluating a CGRP-targeted medication in patients who are using it as a preventive and an as-needed acute treatment for migraine -  Over the course of this open-label extension study, > 80% of patients experienced ≥50% reduction and approximately 50% experienced a 100% reduction -  Complete data from the Phase 3 zavegepant nasal spray study highlight its ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single dose -  New studies showed positive efficacy, safety and pharmacokinetics data for Nurtec ODT as an acute treatment of migraine in adults from China and Korea NEW HAVEN, Conn. , June 13, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Zavegepant Nasal Spray

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported earnings 30 days ago.

Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Up 2.8% Since Last Earnings Report: Can It Continue?

31 new and encore presentations, including three late-breakers and three oral presentations, spotlight robust Nurtec ODT, zavegepant and migraine HEOR data Late-breaking submissions showcase new data for Nurtec ODT in Chinese and Korean patients and patterns of medication utilization in adults using it as an acute and preventive treatment Results from long-term studies of Nurtec ODT as a preventive and acute treatment of migraine showed more than 80% of patients achieved ≥50% reduction in moderate or severe monthly migraine days and approximately half experienced a 100% reduction Other oral presentations included safety and efficacy of zavegepant nasal spray as an acute treatment of migraine and an analysis of placebo responses over time in oral migraine preventive trials NEW HAVEN, Conn. , June 9, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society

AbbVie

Thermo Fisher Scientific

Here are 3 top health care stocks to watch in the stock market right now.

Best Health Care Stocks To Invest In 2022? 3 Names To Watch

The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.

Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA

If approved, zavegepant nasal spray would be the only FDA-approved CGRP receptor antagonist in an intranasal formulation, giving patients a new treatment option that provides ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single dose Zavegepant nasal spray may provide an important alternative for patients who need a quick onset of action or those who cannot take oral treatments due to nausea and vomiting at the time of migraine onset NEW HAVEN, Conn. , May 23, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine

NEW HAVEN, Conn. , May 23, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)

SailPoint Technologies Hlds

Switch

Trecora Resources

NEW YORK , May 16, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN)'s  sale to Pfizer Inc. for $148.50 per share in cash.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BHVN, SWCH, TREC, SAIL

FibroGen

Intra-Cellular Therapies

Seagen

Should investors pay more attention to these biotech stocks?

What Stocks To Buy This Week? 4 Biotech Stocks To Know

NEW YORK , May 13, 2022 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating BioHaven Pharmaceutical Holding Company Ltd. (BHVN), relating to its proposed merger with Pfizer Inc. Under the terms of the agreement, BHVN shareholders will receive 0.5 shares of New Biohaven and $148.50 in cash per share.

Shareholder Alert - The M&A Class Action Firm Announces an Investigation of BioHaven Pharmaceutical Holding Company Ltd. - BHVN

Biohaven Pharmaceuticals Holding Company Ltd. (NYSE: BHVN) was up 70% after the company and Pfizer Inc. (NYSE: PFE) entered a definitive agreement under which Pfizer would acquire the NURTEC ODT maker.

Here is why Biohaven Pharmaceuticals soared 70%

Biohaven (BHVN) is set to be acquired by Pfizer (PFE) for $11.6 billion in cash. The transaction is likely to be completed by early 2023.

Biohaven (BHVN) Up on PFE's Buyout Offer, Q1 Loss Wider

Pfizer

Pfizer Inc's $11.6 billion deal for migraine specialist Biohaven Pharmaceutical has kindled expectations on Wall Street that it may usher in more buyouts as cash-flush drugmakers look to snap up beaten-down smaller biotechs.

Pfizer's $11.6 billion Biohaven buy could spark more biotech deals

Wilmington, Delaware--(Newsfile Corp. - May 11, 2022) - Rigrodsky Law, P.A. is investigating Biohaven Pharmaceutical Holding Co. Ltd. ("Biohaven") (NYSE: BHVN) regarding possible breaches of fiduciary duties and other violations of law related to Biohaven's agreement to be acquired by Pfizer Inc. (NYSE: PFE). Under the terms of the agreement, Biohaven's shareholders will receive $148.50 in cash for each share of Biohaven common stock they own.To learn more about this investigation and your rights, visit:...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Biohaven Pharmaceutical Holding Co. Ltd.

"We have to bring the modern day, novel therapies to those patients, and Pfizer really is the best company to build upon our work," Coric said.

Pfizer deal will help expand reach of migraine pill Nurtec, Biohaven CEO says

NEW YORK , May 10, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE).

SHAREHOLDER ALERT: Weiss Law Investigates Biohaven Pharmaceutical Holding Company Ltd.

BHVN stock is enjoying a nearly 70% jump today after Biohaven Pharmaceutical announced it has been acquired by Pfizer. The post Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?

Why Is Biohaven Pharmaceutical (BHVN) Stock Up Today?

An industry titan wants to buy the biotech for a whopping $11.6 billion.

Why Biohaven Pharmaceutical Stock Soared Today

In a previous discussion on April 28, I speculated that Biogen Inc. ( BIIB , Financial) might be one of the companies interested in acquiring Biohaven Pharmaceutical Holding Co. Ltd. ( BHVN , Financial), a New Haven, Connecticut-based biopharma.

News for Biohaven Pharmaceutical Hld Stock (BHVN)